AR069184A1 - Una composicion farmaceutica que comprende una superestructura (lcz696), de un antagoniste/bloqueante (arb) del recptor angiotensina, e inhibidor de la endopeptidasa neutra (nep). - Google Patents
Una composicion farmaceutica que comprende una superestructura (lcz696), de un antagoniste/bloqueante (arb) del recptor angiotensina, e inhibidor de la endopeptidasa neutra (nep).Info
- Publication number
- AR069184A1 AR069184A1 ARP080104826A ARP080104826A AR069184A1 AR 069184 A1 AR069184 A1 AR 069184A1 AR P080104826 A ARP080104826 A AR P080104826A AR P080104826 A ARP080104826 A AR P080104826A AR 069184 A1 AR069184 A1 AR 069184A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- biphenyl
- dosage form
- oral dosage
- amino
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000003729 Neprilysin Human genes 0.000 title 2
- 108090000028 Neprilysin Proteins 0.000 title 2
- 102000008873 Angiotensin II receptor Human genes 0.000 title 1
- 108050000824 Angiotensin II receptor Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000000903 blocking effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 abstract 4
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000007787 solid Substances 0.000 abstract 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 3
- 229960004699 valsartan Drugs 0.000 abstract 3
- -1 (1S, 3R) -1-biphenyl-4-yl-methyl-3-ethoxy-carbonyl-1-butyl-carbamoyl Chemical group 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 125000004494 ethyl ester group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- OVBFMEVBMNZIBR-UHFFFAOYSA-N -2-Methylpentanoic acid Natural products CCCC(C)C(O)=O OVBFMEVBMNZIBR-UHFFFAOYSA-N 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 238000005056 compaction Methods 0.000 abstract 1
- 238000007907 direct compression Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 238000009490 roller compaction Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Las formas de dosificacion oral solidas, en especial tabletas, de una composicion farmacéutica que comprende un complejo supramolecular, se pueden formar a partir de un proceso de compresion directa o de un proceso de compactacion, tal como compactacion con rodillos. Estas formas de dosificacion oral solida proporcionan un perfil de liberacion inmediata que permite tener una rápida libracion del agente terapéutico. Un complejo supramolecular particularmente util es el propionato-(S)-3'-metil-2'-(pentanoil-{2ö-(tetrazol-5-ilato)-bifenil-4'-il-metil}-amino)-butirato]-hemipentahidrato de [3-((1S,3R)-1-bifenil-4-il-metil-3-etoxi-carbonil-1-butil-carbamoílo) de trisodio. Reivindicacion 15: Una forma de dosificacion oral solida, la cual comprende fracciones de: valsartan, o una sal del mismo, y ácido (2R,4S)-5-bifenil-4-il-5-(3-carboxi-propionil-amino)-2-metil-pentanoico, o etil-éster de etil-éster del ácido (2R,4S)-5-bifenil-4-il-5-(3-carboxi-propionil-amino)-2-metil-pentanoico, o una sal de los mismos, suministrar una cantidad terapéuticamente efectiva de ácido libre de valsartan, o una sal farmacéuticamente aceptable del mismo, y un medio portador, en donde la forma de dosificacion oral proporciona una velocidad de absorcion del ácido libre de valsartan con un tmax de 1 a 2.2 horas en seguida de la administracion de una sola dosis de esta forma de dosificacion, y/o proporciona una exposicion de plasma promedio normalizada a la dosis (AUC0-24) de 230 a 400 nanogramosòhora/mililitro/equivalentes en miligramos, en seguida de la administracion de una sola dosis de esta forma de dosificacion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98566807P | 2007-11-06 | 2007-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069184A1 true AR069184A1 (es) | 2010-01-06 |
Family
ID=40451030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104826A AR069184A1 (es) | 2007-11-06 | 2008-11-04 | Una composicion farmaceutica que comprende una superestructura (lcz696), de un antagoniste/bloqueante (arb) del recptor angiotensina, e inhibidor de la endopeptidasa neutra (nep). |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20100267786A1 (es) |
| EP (4) | EP2295035B1 (es) |
| JP (2) | JP5653218B2 (es) |
| KR (2) | KR101589317B1 (es) |
| CN (2) | CN101848700A (es) |
| AR (1) | AR069184A1 (es) |
| AU (1) | AU2008324878B2 (es) |
| BR (1) | BRPI0823505A2 (es) |
| CA (1) | CA2703598C (es) |
| CL (1) | CL2008003298A1 (es) |
| CY (2) | CY1116280T1 (es) |
| DK (3) | DK3067043T3 (es) |
| EC (1) | ECSP10010160A (es) |
| ES (3) | ES2536514T3 (es) |
| FI (1) | FI3067043T3 (es) |
| GT (1) | GT201000131A (es) |
| HK (3) | HK1143529A1 (es) |
| HR (3) | HRP20230178T3 (es) |
| HU (2) | HUE028866T2 (es) |
| IL (3) | IL262990B2 (es) |
| JO (1) | JOP20080499B1 (es) |
| MA (1) | MA31797B1 (es) |
| MX (1) | MX2010004930A (es) |
| MY (1) | MY153730A (es) |
| NZ (1) | NZ584686A (es) |
| PE (2) | PE20141072A1 (es) |
| PL (3) | PL3067043T3 (es) |
| PT (3) | PT2217205E (es) |
| RU (1) | RU2493844C3 (es) |
| SG (1) | SG185951A1 (es) |
| SI (3) | SI2217205T1 (es) |
| TN (1) | TN2010000200A1 (es) |
| TW (1) | TWI484982B (es) |
| WO (1) | WO2009061713A1 (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2536514T3 (es) | 2007-11-06 | 2015-05-26 | Novartis Ag | Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP) |
| MX2011012627A (es) | 2009-05-28 | 2011-12-14 | Novartis Ag | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. |
| EP2594557B1 (en) | 2009-05-28 | 2016-08-10 | Novartis AG | Substituted aminopropionic derivatives as neprilysin inhibitors |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| CA2807830C (en) * | 2010-08-24 | 2018-04-03 | Novartis Ag | Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| MA37850A1 (fr) | 2012-08-24 | 2018-07-31 | Novartis Ag | Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale |
| EA026989B1 (ru) | 2013-02-14 | 2017-06-30 | Новартис Аг | Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью |
| CN105073762B (zh) | 2013-02-14 | 2017-03-08 | 诺华股份有限公司 | 作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物 |
| US20160206597A1 (en) * | 2013-08-26 | 2016-07-21 | Toni Lynne Bransford | New Use |
| WO2015028941A1 (en) | 2013-08-26 | 2015-03-05 | Novartis Ag | New use |
| WO2015154673A1 (en) * | 2014-04-10 | 2015-10-15 | Zhaoyin Wang | Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases |
| CN105461647B (zh) * | 2014-09-28 | 2018-06-29 | 四川海思科制药有限公司 | 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途 |
| MX2017007426A (es) | 2014-12-08 | 2018-04-20 | Crystal Pharmatech Co Ltd | Formas cristalinas de complejo supramolecular trisodico que comprende valsartan y ahu-377 y metodos de las mismas. |
| CN104473938B (zh) * | 2014-12-30 | 2017-06-09 | 北京瑞都医药科技有限公司 | 一种治疗慢性心衰药物及其制备方法 |
| CN104826115A (zh) * | 2015-04-19 | 2015-08-12 | 浙江巨泰药业有限公司 | 一种抗心衰药物组合物及其制备方法 |
| HRP20230480T1 (hr) | 2015-05-11 | 2023-07-21 | Novartis Ag | Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca |
| US20180140579A1 (en) | 2015-05-29 | 2018-05-24 | Novartis Ag | Sacubitril and valsartan for treating metabolic disease |
| CN106309388A (zh) * | 2015-06-30 | 2017-01-11 | 深圳信立泰药业股份有限公司 | 一种用于心衰治疗的药物组合物及其制备方法 |
| WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
| CN105997993B (zh) * | 2015-07-11 | 2018-03-30 | 麦丽芳 | 一种用于心血管疾病治疗的固体口服型制剂及其制备方法 |
| CN105997994A (zh) * | 2015-07-11 | 2016-10-12 | 凌莉 | 一种固体口服型制剂及其制备方法 |
| CN106176724A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种稳定的固体药物组合物及其制备方法 |
| CN106074421A (zh) * | 2015-07-11 | 2016-11-09 | 凌莉 | 一种提高稳定性的药物组合物 |
| CN106176725A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种提高稳定性的药物组合物及其制备方法和用途 |
| CN106176723A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种固体药物组合物及其制备方法 |
| WO2017012600A1 (en) | 2015-07-20 | 2017-01-26 | Zentiva, K.S. | A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof |
| CN106389374A (zh) * | 2015-08-03 | 2017-02-15 | 深圳信立泰药业股份有限公司 | 一种含有lcz696的药物组合物及其制备方法 |
| JP6598985B2 (ja) | 2015-08-28 | 2019-10-30 | ノバルティス アーゲー | 新規の使用 |
| WO2017037596A1 (en) * | 2015-08-28 | 2017-03-09 | Dr. Reddy's Laboratories Limited | Amorphous solid dispersion of lcz-696 |
| WO2017063581A1 (zh) * | 2015-10-16 | 2017-04-20 | 深圳信立泰药业股份有限公司 | 一种用于心血管疾病治疗的口服制剂及其制备方法 |
| CN105669581B (zh) * | 2015-11-09 | 2017-03-22 | 成都苑东生物制药股份有限公司 | 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物 |
| WO2017085573A1 (en) * | 2015-11-20 | 2017-05-26 | Lupin Limited | Amorphous sacubitril-valsartan complex and process for preparation thereof |
| CN105330609B (zh) * | 2015-12-07 | 2017-12-22 | 南京正大天晴制药有限公司 | 一种制备lcz696的方法 |
| CN105929031B (zh) * | 2015-12-18 | 2018-08-21 | 重庆两江药物研发中心有限公司 | 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法 |
| CN105935358B (zh) * | 2015-12-18 | 2019-06-07 | 重庆两江药物研发中心有限公司 | 一种沙库比曲缬沙坦缓释剂及其制备方法 |
| CN106905253B (zh) * | 2015-12-23 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 一种超分子复合物的结晶 |
| US10722471B2 (en) * | 2016-02-03 | 2020-07-28 | Novartis Ag | Galenic formulations of organic compounds |
| US20190054069A1 (en) * | 2016-02-03 | 2019-02-21 | Novartis Ag | New use of a combination of sacubitril and valsartan |
| CN105748420B (zh) * | 2016-03-04 | 2018-11-06 | 山东省药学科学院 | 一种治疗心力衰竭的lcz696缓释骨架片的制备方法 |
| CN105902506A (zh) * | 2016-06-12 | 2016-08-31 | 佛山市腾瑞医药科技有限公司 | 一种沙卡布曲缬沙坦制剂及其应用 |
| WO2018069937A1 (en) | 2016-10-13 | 2018-04-19 | Mylan Laboratories Limited | Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof |
| WO2018178295A1 (en) | 2017-03-31 | 2018-10-04 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Stable hot-melt extrudate containing valsartan and sacubitril |
| ES2890573T3 (es) * | 2017-03-31 | 2022-01-20 | Tiefenbacher Alfred E Gmbh & Co Kg | Producto extruido de fusión en caliente estable que contiene valsartán y sacubitrilo |
| WO2018211479A1 (en) | 2017-05-19 | 2018-11-22 | Lupin Limited | Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof |
| US11382866B2 (en) | 2017-07-06 | 2022-07-12 | Mankind Pharma Ltd. | Fixed dose pharmaceutical composition of valsartan and sacubitril |
| WO2019020706A1 (en) | 2017-07-28 | 2019-01-31 | Synthon B.V. | PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN |
| WO2019073062A1 (en) | 2017-10-13 | 2019-04-18 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | TABLET CONTAINING VALSARTAN AND SACUBITRIL |
| WO2019180735A1 (en) * | 2018-03-19 | 2019-09-26 | Natco Pharma Limited | Stable pharmaceutical compositions comprising sacubitril-valsartan complex |
| US11877576B2 (en) | 2018-06-22 | 2024-01-23 | Ideaz, Llc | Diphenyl tablets and methods of preparing the same |
| US20210177803A1 (en) | 2018-08-23 | 2021-06-17 | Novartis Ag | New pharmaceutical use for the treatment of heart failure |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| EP3766484B1 (en) | 2019-07-19 | 2021-08-25 | Zentiva, K.S. | Solid pharmaceutical dosage form comprising valsartan and sacubitril |
| KR102545274B1 (ko) | 2020-02-26 | 2023-06-20 | 에리슨제약(주) | 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법 |
| KR20210120560A (ko) | 2020-03-27 | 2021-10-07 | 주식회사 유영제약 | 고함량의 주성분을 포함하는 정제 및 그 제조방법 |
| KR20210138510A (ko) | 2020-05-12 | 2021-11-19 | 에리슨제약(주) | 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제 |
| KR20220091767A (ko) | 2020-12-24 | 2022-07-01 | 주식회사 보령 | 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물 |
| KR102486815B1 (ko) | 2021-01-20 | 2023-01-10 | 주식회사 대웅제약 | Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US608220A (en) | 1898-08-02 | Mechanical movement | ||
| US607355A (en) | 1898-07-12 | Carrier for bicycles | ||
| US607893A (en) | 1898-07-26 | Automatic switch-operating machine | ||
| US735093A (en) | 1903-01-31 | 1903-08-04 | Oscar Greenwald | Elevator-cable guard. |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| US6558699B2 (en) * | 1997-11-17 | 2003-05-06 | Smithkline Beecham Corporation | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
| IL136142A0 (en) * | 1997-11-17 | 2001-05-20 | Smithkline Beecham Corp | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
| US6248729B1 (en) * | 1998-06-17 | 2001-06-19 | Bristol-Myers Squibb Co. | Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination |
| CZ297795B6 (cs) * | 1998-12-23 | 2007-03-28 | Novartis Ag | Tablety obsahující valsartan |
| PL205715B1 (pl) | 2000-07-19 | 2010-05-31 | Novartis Ag | Sól wapniowa walsartanu w postaci tetrahydratu, preparat farmaceutyczny zawierający tę sól, zastosowanie i sposób wytwarzania tej soli |
| CN1615134A (zh) | 2002-01-17 | 2005-05-11 | 诺瓦提斯公司 | 含有缬沙坦和nep抑制剂的药物组合物 |
| US7468390B2 (en) * | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| JP3751287B2 (ja) * | 2002-03-27 | 2006-03-01 | バイエル薬品株式会社 | 小型化されたニフェジピン有核錠剤 |
| WO2003089417A1 (en) | 2002-04-15 | 2003-10-30 | Dr. Reddy's Laboratories Limited | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan) |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| DE602004013405T2 (de) | 2003-03-17 | 2009-05-07 | Teva Pharmaceutical Industries Ltd. | Polymorphe formen von valsartan |
| EP1648515B1 (en) | 2003-07-16 | 2012-11-21 | Boehringer Ingelheim International GmbH | Chlorthalidone combinations |
| GB0402262D0 (en) * | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
| GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| US20090304755A1 (en) * | 2005-10-27 | 2009-12-10 | Raghu Rami Reddy Kasu | Pharmaceutical formulation of losartan |
| US20080227836A1 (en) | 2005-10-31 | 2008-09-18 | Lupin Ltd | Stable Solid Oral Dosage Forms of Valsartan |
| CA2628793C (en) | 2005-11-07 | 2015-01-27 | Stryker Corporation | Patient handling device including local status indication, one-touch fowler angle adjustment, and power-on alarm configuration |
| WO2007056324A2 (en) | 2005-11-08 | 2007-05-18 | Novartis Ag | Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent |
| AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| EP1897537A1 (en) * | 2006-09-04 | 2008-03-12 | Novartis AG | Composition comprising an angiotensin II receptor antagonist |
| ES2536514T3 (es) | 2007-11-06 | 2015-05-26 | Novartis Ag | Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP) |
-
2008
- 2008-11-04 ES ES08848154.4T patent/ES2536514T3/es active Active
- 2008-11-04 PL PL16157767.1T patent/PL3067043T3/pl unknown
- 2008-11-04 SG SG2012081394A patent/SG185951A1/en unknown
- 2008-11-04 EP EP10173506.6A patent/EP2295035B1/en not_active Revoked
- 2008-11-04 US US12/741,251 patent/US20100267786A1/en not_active Abandoned
- 2008-11-04 EP EP22200982.1A patent/EP4186491A1/en active Pending
- 2008-11-04 ES ES10173506.6T patent/ES2587336T3/es active Active
- 2008-11-04 CN CN200880114940A patent/CN101848700A/zh active Pending
- 2008-11-04 PT PT88481544T patent/PT2217205E/pt unknown
- 2008-11-04 DK DK16157767.1T patent/DK3067043T3/da active
- 2008-11-04 CA CA2703598A patent/CA2703598C/en active Active
- 2008-11-04 KR KR1020107009852A patent/KR101589317B1/ko active IP Right Review Request
- 2008-11-04 BR BRPI0823505-8A patent/BRPI0823505A2/pt not_active Application Discontinuation
- 2008-11-04 FI FIEP16157767.1T patent/FI3067043T3/fi active
- 2008-11-04 JO JOP/2008/0499A patent/JOP20080499B1/ar active
- 2008-11-04 CN CN2013101540642A patent/CN103251587A/zh active Pending
- 2008-11-04 RU RU2010123027A patent/RU2493844C3/ru active
- 2008-11-04 EP EP08848154.4A patent/EP2217205B1/en not_active Revoked
- 2008-11-04 DK DK08848154.4T patent/DK2217205T3/en active
- 2008-11-04 MY MYPI2010001722A patent/MY153730A/en unknown
- 2008-11-04 DK DK10173506.6T patent/DK2295035T3/en active
- 2008-11-04 ES ES16157767T patent/ES2939163T3/es active Active
- 2008-11-04 SI SI200831427T patent/SI2217205T1/sl unknown
- 2008-11-04 HU HUE10173506A patent/HUE028866T2/en unknown
- 2008-11-04 HU HUE16157767A patent/HUE061321T2/hu unknown
- 2008-11-04 AU AU2008324878A patent/AU2008324878B2/en active Active
- 2008-11-04 HR HRP20230178TT patent/HRP20230178T3/hr unknown
- 2008-11-04 WO PCT/US2008/082324 patent/WO2009061713A1/en active Application Filing
- 2008-11-04 SI SI200832204T patent/SI3067043T1/sl unknown
- 2008-11-04 JP JP2010533185A patent/JP5653218B2/ja active Active
- 2008-11-04 PE PE2013002393A patent/PE20141072A1/es active IP Right Grant
- 2008-11-04 SI SI200831654A patent/SI2295035T1/sl unknown
- 2008-11-04 MX MX2010004930A patent/MX2010004930A/es active IP Right Grant
- 2008-11-04 AR ARP080104826A patent/AR069184A1/es not_active Application Discontinuation
- 2008-11-04 PT PT101735066T patent/PT2295035T/pt unknown
- 2008-11-04 PT PT161577671T patent/PT3067043T/pt unknown
- 2008-11-04 KR KR1020157033633A patent/KR101700062B1/ko active IP Right Review Request
- 2008-11-04 PL PL10173506.6T patent/PL2295035T3/pl unknown
- 2008-11-04 PE PE2008001886A patent/PE20091390A1/es not_active Application Discontinuation
- 2008-11-04 IL IL262990A patent/IL262990B2/en unknown
- 2008-11-04 NZ NZ584686A patent/NZ584686A/xx unknown
- 2008-11-04 EP EP16157767.1A patent/EP3067043B1/en active Active
- 2008-11-04 PL PL08848154T patent/PL2217205T3/pl unknown
- 2008-11-05 TW TW097142724A patent/TWI484982B/zh active
- 2008-11-05 CL CL2008003298A patent/CL2008003298A1/es unknown
-
2010
- 2010-04-19 IL IL205208A patent/IL205208A/en active IP Right Grant
- 2010-04-30 MA MA32803A patent/MA31797B1/fr unknown
- 2010-04-30 TN TN2010000200A patent/TN2010000200A1/fr unknown
- 2010-05-05 GT GT201000131A patent/GT201000131A/es unknown
- 2010-05-06 EC EC2010010160A patent/ECSP10010160A/es unknown
- 2010-10-19 HK HK10109891.9A patent/HK1143529A1/xx not_active IP Right Cessation
- 2010-10-19 HK HK11107642.4A patent/HK1149721A1/zh not_active IP Right Cessation
-
2014
- 2014-08-12 JP JP2014164022A patent/JP2015038069A/ja not_active Withdrawn
-
2015
- 2015-04-28 HR HRP20150459TT patent/HRP20150459T1/hr unknown
- 2015-05-14 CY CY20151100426T patent/CY1116280T1/el unknown
-
2016
- 2016-08-02 HR HRP20160988TT patent/HRP20160988T1/hr unknown
- 2016-08-08 CY CY20161100778T patent/CY1117883T1/el unknown
- 2016-10-31 HK HK16112495.7A patent/HK1224195A1/zh unknown
-
2017
- 2017-01-03 IL IL249922A patent/IL249922A0/en unknown
-
2020
- 2020-12-02 US US17/109,716 patent/US20210085631A1/en not_active Abandoned
-
2023
- 2023-05-09 US US18/314,745 patent/US20240115536A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069184A1 (es) | Una composicion farmaceutica que comprende una superestructura (lcz696), de un antagoniste/bloqueante (arb) del recptor angiotensina, e inhibidor de la endopeptidasa neutra (nep). | |
| DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| NZ599847A (en) | Pharmaceutical composition comprising a glp-1 agonist and methionine | |
| AR053809A1 (es) | Combinacion de compuestos organicos | |
| CO6160321A2 (es) | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| HK1115070A1 (en) | Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms | |
| CO6270360A2 (es) | Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos | |
| AR041089A1 (es) | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas | |
| EA201290516A1 (ru) | Гетероароматические производные соединения фенилимидазола в качестве ингибиторов фермента pde10a | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| HK1176318A1 (en) | Injection device | |
| HUP0301244A2 (hu) | Rapamicinvegyület alkalmazása szív-és érrendszeri megbetegedések kezelésére szánt gyógyászati készítmény előállítására | |
| WO2006083780A3 (en) | Glucuronidated nebivolol | |
| MX2009011900A (es) | Curacion de herida diabetica. | |
| CL2011003371A1 (es) | Composicion farmaceutica de dosis fija, oral, solida y estable que comprende irbesartan, besilato de amlodipino y excipientes; procedimientos de preparacion; uso en el tratamiento de la hipertension. | |
| NZ597488A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| CY1117261T1 (el) | [4-(5-αμινομεθυλο-2-φθορο-φαινυλο)-πιπεριδιν-1-υλο]-[7-φθορο-1-(2-μεθοξυ-αιθυλο)-4τριφθορο μεθοξυ-1η-ινδολ-3-υλο]-μεθανονη ως αναστολεας τρυπτασης maστοκυτταρων | |
| AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
| ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
| MX2009005798A (es) | Recuperacion de apoplejia. | |
| UY29069A1 (es) | Uso de compuestos tpo miméticos y composiciones farmacéuticas para el tratamiento de la anemia | |
| CA2633077A1 (en) | Solid-state form of amg 706 and pharmaceutical compositions thereof | |
| PE20070622A1 (es) | Administracion de inhibidores de dipeptidil peptidasa | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |